Trial Profile
An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs SHP 610 (Primary)
- Indications Mucopolysaccharidosis III
- Focus Adverse reactions; Pharmacokinetics
- Acronyms CHIL4317
- Sponsors Shire
- 29 Oct 2020 This trial has been completed in Netherlands according to European Clinical Trials Database record.
- 13 Jun 2019 This trial has been completed in France.
- 20 Apr 2017 Planned number of patients changed from 21 to 17.